Skip to main content
MEDIPOSTCO.,LTD. logo

MEDIPOSTCO.,LTD. — Investor Relations & Filings

Ticker · 078160 ISIN · KR7078160009 KO Manufacturing
Open in API
Filings indexed 366 across all filing types
Latest filing 2022-11-04 Earnings Release
Country KR South Korea
Listing KO 078160

About MEDIPOSTCO.,LTD.

https://en.medi-post.co.kr/

MEDIPOST is a biotechnology company specializing in the research, development, and commercialization of stem cell therapeutics and regenerative medicine. The company focuses on addressing unmet medical needs for incurable diseases through its proprietary stem cell platform technology. Its core operations include a cord blood banking service and the development of allogeneic stem cell therapies. Key commercialized products include CARTISTEM®, a treatment for knee cartilage defects and osteoarthritis, and PNEUMOSTEM®, a preventive therapy for bronchopulmonary dysplasia in premature infants. The company's clinical pipeline features next-generation injectable treatments for conditions such as osteoarthritis and diabetic nephropathy.

Recent filings

Filing Released Lang Actions
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Report' (영업(잠정)실적) from MediPost, detailing quarterly financial performance (Revenue, Operating Profit, Net Income) for the 3rd quarter of 2022. It provides key financial highlights and comparisons to previous periods. As this is an initial announcement of quarterly financial results rather than a full comprehensive report, it falls under the 'Earnings Release' category. Q3 2022
2022-11-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when a major shareholder or executive changes their stake in a company. This falls under the category of 'Director's Dealing' (DIRS) as it reports changes in share ownership by a major shareholder (Marvel 2022 Holdings Limited) in Medipost Co., Ltd.
2022-10-13 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from MediPost regarding the adjustment of the conversion price for its 9th series convertible bonds. It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the calculation methodology. This type of disclosure regarding capital structure changes, specifically related to convertible debt instruments, falls under the 'Capital/Financing Update' category.
2022-10-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This type of filing is a mandatory disclosure for major shareholders or insiders when their shareholding status changes. In the provided taxonomy, this corresponds to 'Major Shareholding Notification' (MRQ), as it details the change in ownership percentage and specific securities held by a major shareholder (Marvel 2022 Holdings Limited) in the issuing company (Medipost Co., Ltd.).
2022-09-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory disclosure for major shareholders (10% or more) or executives to report changes in their holdings, often due to conversion price adjustments or acquisitions. In the provided taxonomy, this falls under 'Major Shareholding Notification' (MRQ) as it details the ownership status and changes in holdings for a major shareholder (SkyMedi Limited).
2022-09-30 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from MediPost regarding the adjustment of the conversion price for convertible bonds (8th series). It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the calculation methodology. This falls under capital structure changes related to debt-to-equity instruments, which is best classified as a Capital/Financing Update (CAP).
2022-09-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.